Innovation impresario Shields to leave Pfizer

Share this article:
Innovation impresario Shields to leave Pfizer
Innovation impresario Shields to leave Pfizer
Joe Shields, who leveraged a successful career in product marketing into a broader role as Pfizer's director of worldwide innovation, is leaving later this month for medical device firm LifeScan.

Shields will join the Johnson & Johnson operating company's Global Franchise Marketing group. The position will give him the opportunity to influence the development and design of new products and services around the world to help the millions of people suffering from diabetes.

“This role will enable me to participate more fully in the ‘Connected Health' revolution that, among other things, leverages technology to fundamentally change healthcare around the world,” Shields told MM&M. “I am also very excited to learn more about other areas within marketing, particularly new product development, to broaden my experience and skills. Finally, I have a strong personal connection and commitment to improving the quality of life for people with diabetes.”

Shields--who has been in biopharma for 14 years starting with Astra Merck, followed by AstraZeneca and then Pfizer heritage company Wyeth--had been director of worldwide innovation for about six months. He is perhaps best known for his five-year stint as product director of biologic drug Enbrel, which is co-promoted in the US by Pfizer and Amgen. The drug is the top-selling rheumatoid arthritis med in the US and one of the top-selling biotech drugs globally. Shields is also a member of MM&M's editorial advisory board.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...